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Seventeen healthy women aged 24-45 years with regular
menstrual periods, proven fertility and not using steroidal
contraceptives or IUD were recruited for the study. The
volunteers were followed during one control, one treatment
and one follow-up cycle. Daily morning urine samples were
obtained during the control and the treatment cycle. The
samples were analysed with regard to pregnanediol
glucuronide (P2-G), oestrone glucuronide (Ej-G), oestradiol
(E2), progesterone (P4), LH and creatinine. During the entire
3-month study the subjects kept a record of uterine bleeding
and side effects. The subjects received 50 mg RU486 daily
either on cycle days 7-10 (n = 7) or on cycle days 20-23
(n = 10). An endometrial biopsy was taken on cycle day 10
in the first group and on cycle days 21-28 in the second group
of patients. Treatment during the proliferative phase caused
significant prolongation of the cycle length due to a delay of
the oestrogen and LH surge. However, once the oestrogen
concentration started to increase, the remaining part of the
cycle was normal. The length of the follow-up cycle was
similar to that of the control cycle. The morphology of the
endometrium did not differ from control samples taken from
untreated women at the same time of the cycle. All ovulating
women (n = 9) treated in the mid-luteal phase started to bleed
on the 3rd to 4th day of the treatment. In four of these women
the bleeding was scanty and followed by a menstrual-like
bleeding at expected time, while in the remaining five
volunteers the treatment bleeding was heavier and not
followed by a new bleeding until a month later. The duration
of the secretory phase was 16.5 ± 1 . 3 days in women with
two bleeding episodes and 11.8 ± 1.9 days in women with
one bleeding episode (P < 0.05). The hormonal parameters
were similar in both groups up to the start of the treatment.
In the patients with one bleeding episode, the treatment was
associated with a reduction in progesterone concentration,
while in the patients with two bleeding episodes the pro-
gesterone concentration remained elevated until the second
bleeding episode. Light microscopic examination of the
endometrium revealed unique changes in the endometrial
morphology. The results indicate that RU486 acts mainly on
the endometrium but a direct or indirect effect on the corpus
luteum cannot be excluded. The age of the corpus luteum may
be of importance for its susceptibility to RU486 treatment.
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Introduction
The presence of a normal corpus luteum, secreting adequate levels
of progesterone, is a prerequisite for implantation of the fertilized
ovum and for the maintenance of very early pregnancy, both in
animals and in the human. Compounds which interfere with
corpus luteum function, the production of progesterone or its
effect on the target organ are therefore potential candidates for
use in a postovulatory mode of fertility control.
Prostaglandin F ^ has been shown to be luteolytic in many
animal species (Pharris, 1971; McCracken etal., 1972;
Behrman, 1979). However, it has not been possible so far to
demonstrate such an effect in the human. Intermittent, mid-luteal
administration of LHRH agonist has been shown to be capable
of causing a decrease in serum progesterone levels and premature
onset of menstruation (Bergquist et al., 1980a), but the timing
of the LHRH agonist treatment seemed, however, to be critical
for its effectiveness (Bergquist et al., 1980b). This fact, together
with the finding that simultaneous administration of HCG
prevented die luteolytic effect of the agonist, indicates that it is
unlikely that these types of compounds could be developed into
effective postovulatory contraceptive agents.
More recently, compounds affecting progesterone metabolism
or the peripheral action of progesterone have become available
for clinical testing. To the former belongs epostane, a competitive
inhibitor of 3/3-hydroxy-steroid-dehydrogenase, which converts
pregnenolone to progesterone (Pattison et al., 1985); to the latter
RU486, which acts as an antiprogestin (Philibert et al, 1985).
RU486 has a high affinity for the progesterone receptor and acts
at the uterine target organs, i.e. the endometrium, myometrium
and decidua. An effect on the release of gonadotrophins from
the pituitary has also been reported (Schaison et al., 1985).
The aim of the present study was to evaluate the effect of
RU486 on bleeding pattern, hormonal parameters and on endo-
metrial morphology, when administered during the follicular or
secretory phase of die menstrual cycle.
Materials and methods
Subjects
Seventeen healthy women aged 25—45 years with regular
menstrual cycles (between 25 and 35 days) volunteered for the
study. All subjects were of proven fertility and none of them had
used steroidal contraceptives or an IUD during a minimum of
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3 months prior to the study. On admission, a gynaecological
examination was performed and the volunteers were instructed
to use barrier methods for contraception during the entire study
period.
Study design
The study included one control, one treatment and one follow-
up cycle. In the treatment cycle, the subjects received 50 mg
RU486 orally between 8.00 and 10.00 a.m. either on cycle days
7—10 (preovulatory phase treatment group) or on cycle days
20—23 (postovulatory phase treatment group). Seven subjects
were allocated to the former group and ten to the latter group.
During the control and treatment cycle, daily morning urine
was collected and kept frozen until assayed. The samples were
analysed with regard to pregnanediol glucuronide (P2-G),
oestrone glucuronide (E,-G), oestradiol (EJ, progesterone (P4),
creatinine (C) and LH. During the treatment cycle 10 ml of blood
was also taken on cycle days 4 - 1 4 and 17-27 when RU486
was given in the preovulatory and postovulatory phases respec-
tively. The plasma was analysed with regard to cortisol. During
the entire 3-month study, the subjects kept a record of uterine
bleeding and side effects.
Hormone assays
The analyses of P2-G and E]-G were carried out by radio-
immunological methods described by Cekan et al. (1986). LH
and cortisol were estimated by radioimmunoassay assay tech-
niques described by Sufi et al. (1986). Radioimmunoassays of
E2 and P4 in urine were performed according to Beksac et al.
(1984) and Beksac and Cekan (1985). In addition, the C
concentration in urine was assessed by routine methods, based
on the reaction of C with picric acid (Heinegard and
Tiderstrom, 1973). RU486 was found not interact with the steroid
measurements (S.Z.Cekan, personal communication).
Calculations of hormone values
The preovulatory phase was defined as the period from the first
day of the menstrual bleeding to the day of the LH surge
(inclusive), whereas the postovulatory phase was defined as the
period from day LH+1 to the day of preovulatory progesterone
concentrations of less than the mean value ± 2 SD. All hormonal
measurements in urine were expressed as nmol/mmol creatinine
(Metcalf and Hunt, 1976). The urinary steroid concentrations
in each individual subject were thereafter plotted relative to either
the day of the LH surge or the first day of menstruation, and
the area under the curve for the corresponding time periods in
the control and treatment cycles was calculated. The areas under
the curve were calculated as sums of partial areas obtained
according to the following formula:
level a + level b . level b + level c
area = time x + time x
etc., where time is expressed in days and a, b and c are the
successive hormonal levels expressed in nmol/mmol creatinine.
A log normal distribution (Gaddum, 1945) was assumed for all
steroid levels and areas under the curve. Paired /-test or analysis
Table I. Effect of oral
Treatment
RU486 50 mg daily
Control cycle
Follicular phase
Secretory phase
Total
Treatment cycle
Follicular phase
Secretory phase
Total
Follow-up cycle
Total length
administration of RU486 on 1
Cycle
Days
13.6
12.6
26.1
21.4
11.6
33.0
28.0
length
7-10
±
±
±
±
±
±
±
1.8"
2.2
2.7"
3.41
1.9
3/r1
4.8
(days)
Days
One
13.2
12.4
25.6
12.4
11.8
22.6
26.2
cycle
20-23
bleeding
±
±
±
±
±
±
±
1.5
2.1
2.5
1.5
1.9"
1.8°
1.3
length (mean
Two
14.2
13.0
27.2
14.0
16.5
305
25.2
± SD)
bleedings
±
±
±
±
±
±
±
2.2
2.2
0.9
2.2
1.3"
2.6C
2.2
Values with same superscript are significantly different: V < 0.01; bP < 0.05;
CP < 0.05; "P < 0.01.
CONTROL CYCLE
0 J
-20 -16 16
Fig. 1. Geometric mean of pregnanediol glucuronide and oestron-
glucuronide in morning urine during control and treatment cycle in
seven patients who received 50 mg RU486 daily on days 7 -10 of
the menstrual cycle.
of variance was used for the statistical evaluation of the results,
except for calculating differences between length of cycle periods
when the Wilcoxon two-sample Rank test was preferred.
Morphological methods
An endometrial biopsy was taken on cycle day 10 in the
preovulatory phase treatment group. In the postovulatory phase
treatment group the endometrial biopsy was initially planned to
be taken on the 23rd day of the cycle. However, since all subjects
started to bleed on the third or fourth day of RU486 intake, i.e.
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Tab*
LH
E,-G
E,
P4
P7-G
n . Hormone
RU486 50 mg
Control cycle
1-14
(cycle days)
95 ± 42"
levels IT
orally,
- 8 to
108
62
1 morning urinary samples during different parts of the
proliferanve phase
1 LH LH + 1 to +10
± 5 5 115 ±
± 1 4 62 ±
0 43 ± 0.14 0 35 ± 0 08 0.33 ±
2.2 ±
71
17
0.0s
0.9
9428 ± 3773
Treatment cycle
1-14
(cyde days)
56 ± 26'
1 0.36 ± 0.21
- 8 to
167
58
0 35
control
LH
±
±
±
161
18
0
and treatment
LH + 1 1
162
61
.17 0.34
1.9
8343
to
±
±
• ±
±
±
cydes
+ 10
98
16
0)
(c)
(b)
(c)
0 10 (b)
0.4
3659
(c)
(b)
(c)
(b)
(c)
RU486 50mg
Control cyde
LH+1 to +10
(cyde days)
112 ±
120 ±
50 ±
53 ±
0.32 ±
0 32 ±
1.6 ±
1.9 ±
orally.
68
30
7
25
020
0.14
0.7
0.1
6254 ± 3462
10 822 ±4411
secretory phase
Treatment cyde
LH+1 1
100
135
51
47
0.21
0.33
1.4
1.6
7697
6291
0 +10
± 44
± 32
± 11
± 18
± 0.03
± 0 16
± 0.6
± 0.2
± 6115
± 974
LH + 8to
0.6 ±
1.3 ±
3640 ±
6250 ±
+ 16
0.2b
0.5b
3162
2112
After correction for the creannine concentration, the area under the curve was calculated and expressed in nmol/mmol creannine, for oestrooe glucuronide (E,-G), oestradiol
progesterone (P^) and pregnanediol glucuronide (P2-G) and in IU/mmol creannine for LH.
The values are mean ± SD
Values with same superscript are significantly different: 'P < 0 05; bP < 0 05.
Subjects with one (b) and two (c) Weeding episodes.
on day 22 or 23 of the cycle, the biopsies from the women were
taken either before the bleeding (cd 21;2 subjects), at start of
bleeding (cd 23 ;4 subjects) or after the bleeding had stopped (cd
25,26,27;3 subjects).
Specimens were taken with a Randall curette from the anterior
and lateral walls of the uterine cavity without prior cervical
dilatation or local anaesthesia. The biopsy material was
immediately fixed in Bouin's solution and used for light
microscopic examination after embedding in paraffin and staining
with haematoxylin.
The material prepared for light microscopy was assessed by
morphometric analyses (X 400) measuring the number of
glands/mm2, number of glandular and stromal mitoses/1000
glandular and stromal cells respectively, glandular diameter, cells
with basal vacuolation/1000 glandular cells and glandular
epithelial height (Johannisson etal., 1987).
The study was approved by the Swedish Drug Regulatory
Authorities and the Ethical Committee of the Karolinska Hospital.
Results
Preovulatory group
None of the seven subjects treated during the preovulatory phase
of the menstrual cycle started to bleed during treatment. In all
subjects the treatment cycle (33.0 ± 3.7 days; mean ± SD) was
significantly (P < 0.05) prolonged in comparison with the
control cycle (26.1 ± 2.4 days). The hormonal data showed that
the prolongation of the treatment cycle was due to a significantly
longer preovulatory phase (21.4 ± 3.4 days) than in the control
cycle (13.6 ± 1.8 days) {P < 0.05). The subsequent post-
ovulatory phase was of normal length (Table I). The urinary
concentration of E)-G during the first 14 days of the cycle was
significantly lower during the treatment than during the control
cycle. However, when the urinary levels of P2-G, P4, E2, Ei-G
CONTROL CYCLE
o
UJ
a.
n.
2000
1200-
400-
0 J
2000 1
1200 -
400-
0 J
TREATMENT CYCLE
- 2 0 -16 -12 - 8 - 4 0
CYCLE DAY
• 16
Fig. 2. Mean levels of pregnanediol glucuronide in morning urine
during control and treatment cycle in nine patients treated with
RU486 25 mg twice daily on cycle days 20-23 . Five patients (I)
had only one bleeding, occurring on the 3rd day of treatment. Four
patients (IT) in addition to bleeding during treatment experienced
bleeding ~ 1 week later.
and LH during cycle days L H - 8 to LH peak and LH + 1 to
LH +10 in the treatment cycle were compared with those in the
control cycle, no differences were found (Figure 1, Table II).
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Thus, the reason for the longer preovulatory phase was a delay
in the oestrogen and LH surges. Once the oestrogen concentration
started to increase, the remaining part of the cycle seemed
hormonally normal. The length of the follow-up cycle was also
normal.
Five of the seven women provided sufficient biopsy material
for light microscopic assessment. In two women the biopsy
specimen was too small for morphometric analysis. The light
microscopic appearance of the endometrium was identical to that
found in the normally menstruating woman (Johannisson et al.,
1987), indicating that treatment with RU486 during the prolifer-
ative phase of the cycle does not alter endometrial morphology.
Postovulatory group
Ten subjects were treated in the postovulatory phase, but one
rmriol/l
400-
300-
200-
100-
. 1/
. \1
.
y
/
\
\ *--
RU 486
1 1
10 Days
Fig. 3. Plasma cortisol levels before, during and after oral
administration of 50 mg RU486 daily for 4 days in 16 non-pregnant
women. The values are geometric means ±95% confidence limits.
of them was excluded since the hormonal analyses revealed that
the woman had had a late ovulation and in fact had been treated
during the preovulatory period. The remaining nine women
started to bleed on the 3rd or 4th day of treatment. In four subjects
the induced bleeding was followed by a second bleeding episode
at approximately the expected time of their normal menstruation.
In the remaining five subjects, the next bleeding did not occur
until ~ 4 weeks later as shown in Table I. In the women who
had two bleeding episodes the RU486 treatment started on days
4, 5, 6 and 9 after the LH surge and in those with only one
bleeding episode RU486 intake started on days 6, 7, 7, 8 and
11 after the LH surge.
Based on urinary progesterone concentration, the secretory
phase was 11.8 ± 1.9 days for the group with one bleeding
episode and 16.5 ± 1.3 days for the group with two bleeding
episodes (P < 0.05). The duration of the follow-up cycles did
not differ from the corresponding control cycles (Table I).
The concentration of P4 during and after treatment with
RU486 (LH+8 to LH + 16; median starting day of RU486
treatment LH+7) was also significantly lower in the group with
one bleeding episode. However, in the earlier part of the secretory
phase (LH+1 to LH+10), there were no differences in the
hormonal levels between the two treatment groups, or between
these and the corresponding parts of the control cycle (Figure
2, Table II).
Plasma cortisol concentration showed a slight but significant
increase (P < 0.05) during RU486 treatment when compared
with the values before and after the RU486 administration (Figure
3).
Seven of die nine biopsies provided sufficient endometrial
material for a complete light microscopic morphometric assess-
ment (Table IE).
Correlated to the LH surge, the biopsies during the post-
ovulatory phase were taken on LH+7 (one subject), LH+8 (two
subjects), LH + 10 (one subject), LH + 12 (two subjects) and
LH +11, +13 and +17 (one subject each). In two women only
Table i n . The
Subject
Group (b)
RA
MH
CL
GJ
MR
Mean ± SD
or range
Group (c)
CA
GG
AJ
MK
effect of RU486 on the endometrium
No. of
glands/mm2
a
11.4
19.4
27.5
a
19.4 ± 8.0
39.5
26.1
8.0
19.4
Glandular
mitoses/
1000 cells
0
0
0
0
0
0
1
0
3
26
Stroma
mitoses/
1000 cells
0
0
3
0
0
0 - 3
0
0
1
1
when administered
Glandular
diameter
Oun)
_•
70.7
68.7
18.7
_»
52.7 ± 29.5
45.0
44.0
53.7
46.0
during cycle
No. of
vacuolated
cells/1000
cells
0
-
0
0
0
0
0
0
130
70
days 20-23
Glandular
epithelial
height Gun)
24.5
15.5
19.2
16.2
18.0
15.1 ± 8.5
18.5
17.0
22.2
26.0
Leukocytk
infiltration
3
0
0
3
3
0 - 3
2
2
1
0
Dating
Menstrual
Late secretory
Late secretory
Menstrual
Menstrua]
Premenstrual
Menstrua]
Irregular secretory
activity
Proliferative phase
Time of
cycle at
biopsy
LH + 10
LH + 8
LH + 12
LH + 12
LH + 11
LH+7
LH+8
LH+13
LH + 17
Time of
biopsy from
RU486 start
(days)
4
2
2
7
4
4
4
8
9
Group (b) one bleeding episode; group (c) two bleeding episodes.
•Material too regressive to be assessed.
Q1R
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a partial assessment could be made because the endometrial
material had undergone strong regression. In these cases the
glands had either collapsed or showed a partial breakdown and
the number and diameter of the glands therefore could not be
assessed.
In three of the five women with a single bleeding episode, the
endometrium showed regressive changes as well as bleeding and
a heavy infiltration of leukocytes. The biopsies in these three cases
were taken on day 4 of RU486 treatment and were compatible
with the structure observed during normal menstruation. In the
remaining two subjects with one single bleeding episode, the
biopsies were obtained on day 2 of RU486 treatment. In these
women the histological pattern corresponded to the late
postovulatory phase of a normal cycle and showed early
regression changes.
In two of the four women with two bleeding episodes the biopsy
was taken on the fourth day of RU486 treatment. In both subjects
a situation corresponding to premenstrual and menstrual phase
was observed. It is noteworthy that these regressive changes,
which usually do not occur before LH + 12 of the normal
menstrual cycle, were observed already on days LH+7 and +8.
In the two other women the biopsy was taken on either the 13th
or the 17th day after the LH surge, when the first bleeding episode
had stopped. In one woman, the endometrium showed irregular
secretory changes suggesting a persistent effect of progesterone,
and, in the other, proliferative changes were observed, with high
mitotic activity of the glands.
Discussion
The results of the present study indicate that a 4-day admin-
istration of 50 mg RU486 starting from the 4th day or later after
the LH peak invariably resulted in uterine bleeding on the 3rd
or 4th day of treatment, whereas the same treatment did not have
any effect on the endometrium when given on cycle days 7-10
of the preovulatory phase. However, the latter treatment regimen
prolonged the duration of the preovulatory phase and delayed
the oestrogen rise and LH surge. It is noteworthy that, once
follicular development resumed, the magnitude of the oestrogen
rise and LH peak, as well as duration and hormonal levels of
the postovulatory phase, were similar to those found in the control
cycles.
The delay of the preovulatory oestradiol rise as well as the
LH surge could be due to an effect of RU486 either on the
hypothalamic — pituitary axis influencing the release of
gonadotrophins, or directly on the follicle. To what extent RU486
affects the release of gonadotrophins (if administered during the
preovulatory phase of the cycle) is unclear. Such an effect could
not be demonstrated in the monkey (Healy et al., 1983; Asch
and Rojas, 1985). On the other hand, RU486 administered to
normal women, in the mid-luteal phase of the menstrual cycle
(Schaison et al., 1985) and to postmenopausal women (Gravanis
et al., 1985), resulted in a decrease in mean LH levels and the
disappearance of pulsatile release. It is noteworthy, however, that
in women with anovulatory cycles no effect on LH could be
observed (Schaison et al., 1985).
It is well known that hormonal production of granulosa cells
is of major importance for the regulation of follicular maturation
(McNatty, 1981). Studies in vitro on human granulosa cells
isolated from follicular fluid and mature follicles, have shown
that the addition of RU486 causes significant suppression of
progesterone production by decreasing the activity of 3/3-hydroxy
steroid dehydrogenase (Dimattina et al., 1986). As recent studies
indicate that substantial amounts of the compound can be found
in follicular fluid (A.A.Templeton etal., in preparation),
following oral administration of RU486, and human ovarian
progesterone receptors are present in the granulosa cells (Jacobs
etal., 1980), it is at least possible that RU486 may directly
influence follicular maturation either by a temporary halt or by
a premature follicular disruption. In the latter case ovulation will
be delayed until a new leading follicle has been recruited.
Except for the delay in the development of the LH peak and
of the maximal levels of urinary oestradiol, the adminstration
of RU486 in the preovulatory phase did not seem to have any
significant effect. None of the subjects in the preovulatory phase
treatment group started to bleed during or immediately after the
tablet intake. The morphometric analysis of the light microscopic
material did not differ from the findings of the endometrial
biopsies taken from untreated women in the corresponding period
of the cycle.
When 50 mg RU486 was administered during the post-
ovulatory period on cycle days 20-23, all patients started to bleed
on the third or fourth day of treatment. In five patients, the
bleeding was similar to that of normal menstruation, while in
the remaining four patients, the bleeding was more scanty and
was followed by a second bleeding episode at approximately the
expected time of menstruation. The time interval from the LH
surge to the day progesterone levels reached preovulatory values
was significantly shorter in the women with one bleeding episode
than in the subjects with two bleeding episodes. In the first group
of subjects the progesterone decrease occurred during RU486
intake. In the second group of subjects the progesterone levels
remained unchanged until the second bleeding episode.
The effect of RU486 on the bleeding pattern could be due to
an effect on the endometrium, on corpus luteum function and/or
on the hypothalamic pituitary system. Several investigations
indicate that the local effect on the endometrium is the most
important. RU486 has a high affinity for the uterine progesterone
receptor and antagonizes the effect of progesterone on the endo-
metrium (Herrmann et al., 1985; Philibert et al., 1985). Further-
more, Croxatto etal. (1985) demonstrated in the human female,
and Asch and Rojas (1985) in the rhesus monkey, that RU486
provoked bleeding which occurred in spite of high progesterone
levels during pseudopregnancy induced by HCG administration.
Nevertheless, the shorter duration of the postovulatory phase and
the premature decrease of progesterone in the subjects with one
bleeding episode, compared with the subjects with two bleeding
episodes, indicate that RU486 can also influence luteal function
either directly or through an effect on pituitary gonadotrophin
secretion. The results of Schaison et al. (1985) support both these
alternatives; i.e. the drug may impair, simultaneously or
separately, luteal function and gonadotrophin secretion in a dose-
dependent manner. Studies in vitro also indicate that RU486 may
have a direct effect on the progesterone production of human
granulosa cells (Dimattina et al., 1986). The variation in response
to RU486 treatment could depend upon the age of the corpus
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luteum. The finding that the women with two bleeding episodes
tended to have been treated earlier in relation to the LH surge
than those with one bleeding episode supports such a possibility.
It is well known that several characteristics of the corpus luteum
are modified during the normal postovulatory phase of the
menstrual cycle including morphological changes (Corner, 1956),
a decrease in the number of LH receptors (Yamoto et al., 1986),
and an increase in LH inhibitory protein (Nakano et al., 1985).
It has been suggested that besides a local effect on the endo-
metrium, RU486 influences the release of LH (Baulieu, 1985).
Schaison et al. (1985) have reported, as mentioned previously,
decreased LH levels and the disappearance of the pulsatile pattern
in a dose-dependent way when women were treated with RU486
in mid-luteal phase. In the present study the mean LH level was
unaffected during RU486 treatment on days 20—23 of the
menstrual cycle. These findings are in agreement with those of
Asch and Rojas (1985) in the rhesus monkey and of Croxatto
et al. (1987) in the human female, who could not demonstrate
any decrease in mean gonadotrophin levels. However, in neither
of the above-mentioned studies nor in this was the experimental
design suitable for measuring the pulsatile release of LH.
Besides an antiprogestin effect, RU486 also has antigluco-
corticoid activity. An increase in plasmid cortisol levels has been
reported previously during treatment with RU486 in women in
early pregnancy (Kovacs et al., 1984). The present study
indicates that the same is also true in non-pregnant women. The
increase was, however, slight and the concentrations of plasma
cortisol never exceeded normal limits. Similar results have also
been reported by Croxatto et al. (1985) but not by Schaison
et al. (1985). The reason for this discrepancy remains to be
elucidated.
In the present study the light microscopic examination of the
biopsies obtained on day 4 of the RU486 administration did not
reveal any significant effect on the endometrium, when the
compound was given in the proliferative phase. This is somewhat
contradictory to the findings of Koering et al. (1986) in the
endometrium of castrated oestradiol-treated monkeys. These
authors claimed that RU486 had a weak progestational effect on
the proliferative endometrium. The difference may be explained
by the fact that the design of the experiment was different, but
it is also likely that species difference may play a role. Chillik
et al. (1986) carried out experiments in non-castrated monkeys,
giving the RU486 in the mid-luteal phase. Their results were
similar to ours and regressive changes were reported to occur
in the endometrium with a uniform shedding of the mucosa and
subsequent bleeding. As in the monkeys, the endometrial
bleedings occurred within 48 h and 96 h after the RU486
administration. In the monkeys the shedding of the endometrium
was considered to be quite deep. The present study was, however,
carried out in thin endometrial strips representing only the upper
functional layer. This part of the human endometrium had
undergone a complete regression of the mucosa with a strong
leukocytic infiltration on the 4th day of the administration. It is
noteworthy that this strong regression and complete shedding of
the endometrium also occurred on the 4th day of the RU486
treatment in women having two bleeding episodes. The presence
of the second bleeding episode is therefore difficult to explain.
In one woman, the endometrial biopsy was taken after the
bleeding had stopped. In this case a proliferation was found,
suggesting the commencement of a new endometrial cycle. In
another case the biposy was also obtained after the bleeding had
stopped and the mucosa revealed an abnormal secretory activity.
In this case some midluteal-phase endometrium may have been
conserved, perhaps due to high progesterone values, and the
second bleeding episode resulted in a more complete shedding.
This hypothesis, however, is contradicted by the study of Chillik
et al. (1986) in cynomolgus monkeys where the shedding of the
endometrium was found to be uniform in the entire uterus. The
results of the present study do not allow any definite conclusions
in this respect.
In view of the fact that RU486 acts as a strong antiprogestin
at the receptor level, further in-depth studies may be of
importance into factors mediating the effect on the pituitary and
ovarian activity, the endometrium and the onset of endometrial
bleeding. Such studies may facilitate the future possible clinical
use of the antiprogestin to prevent implantation and for
termination of very early pregnancy.
Acknowledgements
We are indebted to Drs Paul F.A.Van Look and A.Ullman who made
many valuable suggestions during the preparation of the manuscript. The
expert technical assistance of Ms Ingrid Vedin and Mrs Astrid Haggblad
of Stockholm, Mrs Erika Jakobsson-Strom and Mrs Fabienne Simon
of Geneva, is gratefully acknowledged. The present study was supported
by the WHO Special Programme of Research, Development and
Research Training in Human Reproduction, Geneva, Switzerland, and
by the Swiss National Research Foundation, grant 3.955—0.84. The
compound RU486 was kindly supplied by Roussel Uclaf, Paris, France.
References
Asch,R.H. and Rojas.F.J. (1985) The effect of RU486 on the luteal
phase of the rhesus monkey. J. Steroid Biochem., 22, 227—230.
Baulieu,E.E. (1985) RU486: an antiprogestin steroid with contragestive
activity in women. In Baulieu,E.E. and Segal,S.J. (eds), The Anti-
progestin Steroid RU486 and Human Fertility Control. Plenum Press,
New York, pp. 1 -26 .
Behrman.H.R. (1979) Prostaglandins in hypothalamo-pituitary and
ovarian function. Annu. Rev. Physiol., 41, 685—700.
Beksac.M.S. and Cekan.S.Z. (1985) Reliability of progesterone
measurements in urine. J. Gin. Chem. Clin. Biochem., 23, 183-186.
Beksac.M.S., Wang.Y. and Cekan,S. (1984) Validity of the radio-
immunoassay of unconjugated estradiol in urine. Acta Reprod Turcica,
5, 55-62.
Bergquist,C, Nillius,S.J. and Wide,L. (1980a) Effects of a luteinizing
hormone-releasing hormone agonist on luteal function in women.
Contraception, 22, 287-293.
Bergquist,C, Nillius.S.J. and Wide.L. (1980b) Luteolysis induced by
a luteinizing hormone-releasing hormone agonist is prevented by
human chorionic gonadotrophin. Contraception, 22, 341 —347.
Cekan.S.Z, Beksac,M.S,. Wang.E., Shi.S., Masironi.B., Landgren,
B.-M. and Diczfalusy.E. (1986) The prediction and/or detection of
ovulation by means of urinary steroid assays. Contraception, 33,
327-345.
Chillik.C.F., HsiuJ.G., Acosta.A.A., van Uem.J.F.H.M. and
Hodgen.G.D. (1986) RU486-induced menses in cynomolgus monkeys:
uniformity of endometrial sloughing. Fertil. Steril, 45, 708-712.
Comer.G.W.Jr (1956) Histologic daring of corpus luteum of
menstruation. Am. J. Anat., 98, 377-401.
920
Croxatto.H.B., Spitz.I.M., Salvatierra.A.M. and Bardin.C.W. (1985)
The demonstration of the antiprogestin effects of RU486 when
administered to the human during hCG-induced pseudopregnancy. In
Baulieu.E.E. and Segal.S.J. (eds), The Antiprogestin Steroid RU486
and Human Fertility Control. Plenum Press, New York, pp. 263-269.
Croxatto.H.B., Salvatierra,A.M., Romero.C. and Spitz,I.M. (1987)
Late luteal phase administration of RU486 for three successive cycles
does not disrupt bleeding patterns or ovulation. J. Clin. Endocrinol.
Metab., 65, 1272-1277.
Dimattina,M., Albertson,B., Seyler.D.E., Loriaux.D.L. and Falk.R.J.
(1986) Effect of the antiprogestin RU486 on progesterone production
by cultured human granulosa cells: inhibition of the ovarian 3B-
hydroxy steroid dehydrogenase. Contraception, 34, 199—206.
Gaddum,J. (1945) Lognormal distributions. Nature, 156, 463—466.
Gravanis,A., Schaison.G., George.M., de BruxJ., Stayaswaroop.P.G.,
Baulieu.E.E. and Robel.P. (1985) Endometrial and pituitary response
to the steroidal antiprogestin RU486 in postmenopausal women. J.
Clin. Endocrinol. Metab., 60, 156-163.
Healy.D.L., Chrousos.G.P., Shuhe.H.M., Williams.R.F., Gold.P.W.,
Baulieu.E.E. and Hodgen,G.D. (1983) Pituitary and adrenal responses
to the anti-progesterone and anti-glycocorticoid steroid RU486 in
primates. J. Clin. Endocrinol. Metab., 57, 863-865.
Heinegard.D. and Tiderstr6m,G. (1973) The determination of serum
creatinine by a direct colorimetric method. Clin. Chim. Acta, 43,
305-310.
Herrmann,W.L., Schindler.A.M., Wyss,R. and Bishof.P. (1985) Effects
of the antiprogesterone RU486 in early pregnancy and during the
menstrual cycle. In Baulieu.E.E. and Segal,S.J. (eds), The
Antiprogestin Steroid RU486 and Human Fertility Control. Plenum
Press, New York, pp. 179-198.
Jacobs.B.R., Suchocki.S. and Smith.R.G. (1980) Evidence for a human
ovarian progesterone receptor. Am. J. Obstet. GynecoL, 138,
332-336.
Johannisson.E., Landgren,B.-M., Rohr.H.P. and Diczfalusy,E. (1987)
Endometrial morphology and peripheral hormone levels in women
with regular menstrual cycles. Fertil. Sterii, 48, 401-408.
Koering,M.J., Healy.D.L. and Hodgen.G.D. (1986) Morphologic
response of endometrium to a progesterone receptor antagonist,
RU486, in monkeys. Fertil. Sterii., 45, 280-287.
Kovacs.L., Sas,M., Resch.B.A., Ugocsai.G., Swahn.M.L.,
Bygdeman.M. and Rowe,P.J. (1984) Termination of very early
pregnancy by RU486, an antiprogestational compound. Contracep-
tion, 29, 399-410.
McCracken^.A., CarlsonJ.C, Glew.M.E., Godnig.J.R., Baird,D.T.,
Green,K. and Samuelsson.B. (1972) Prostaglandin identified as a
luteolytic hormone in sheep. Nature, 238, 129-134.
McNatty.K.P. (1981) Hormonal correlates of follicular development in
the human ovary. Aust. J. Biol. Sci., 34, 249-268.
Metcalf.M. and Hunt.E.G. (1976) Calculation of estrogen excretion rates
from urinary estrogen to creatinine ratios. Clin. Biochem.,9,15—Tl.
Nakano.R., Iwasaki,M. and Yamoto.M. (1985) Luteinizing hormone
receptor binding inhibitor in aqueous extract of human corpus luteum.
GynecoL Obstet. Invest., 20, 4 5 - 5 1 .
Pattison.N.S., Webster.M.A., Phipps.S.L., Anderson.A.B.M. and
Gillmer.M.D.G. (1985) Inhibition of 3/3-hydroxy steroid
dehydrogenase activity in first and second trimester human pregnancy
and the luteal phase using Epostane. Fertil. Sterii., 42, 875-881.
Pharris.B. (1971) Prostaglandin induction of luteolysis. Proc. NYAcad
Sci., 180, 434-444.
Philibert.D., Moguilewsky.M., Mary.I., Lecaque.D., Toumemine.C,
Secchi,J. and Deraedt,R. (1985) Pharmacological profile of RU486
in animals. In Baulieu.E.E. and Segal.S.J. (eds), The Antiprogestin
Steroid RU486 and Human Fertility Control. Plenum Press, New
York, p. 49.
Schaison.G., George,M., Lestrat.M., Reinberg.A. and Baulieu.E.E.
RU486 and menstrual cycle
(1985) Effects of the antiprogesterone steroid RU486 during midluteal
phase in normal women. J. Clin. Endocrinol. Metab., 61, 484—489.
Sufi.S.B., Donaldson.A. and Jeffcoate.S.L. (1986) Method Manual.
WHO Programme for the Provision of Matched Assay Reagents, 10th
edn., Geneva, Switzerland.
Yamoto.N., Nakano.R., Iwasaki.M., Dcoma.H. and Furukawa,K. (1986)
Luteinizing hormone receptors in human ovarian follicles and cor-
pora lutea during the menstrual cycle. Obstet. Gynecol., 68, 200—203.
Received on December 16, 1987; accepted on April 12, 1988.
921
